175 related articles for article (PubMed ID: 15140340)
1. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
Dobs AS; Matsumoto AM; Wang C; Kipnes MS
Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
3. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.
Korbonits M; Slawik M; Cullen D; Ross RJ; Stalla G; Schneider H; Reincke M; Bouloux PM; Grossman AB
J Clin Endocrinol Metab; 2004 May; 89(5):2039-43. PubMed ID: 15126518
[TBL] [Abstract][Full Text] [Related]
4. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW; Wyllie MG
BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men.
Ross RJ; Jabbar A; Jones TH; Roberts B; Dunkley K; Hall J; Long A; Levine H; Cullen DR
Eur J Endocrinol; 2004 Jan; 150(1):57-63. PubMed ID: 14713280
[TBL] [Abstract][Full Text] [Related]
6. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
8. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
9. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
[TBL] [Abstract][Full Text] [Related]
11. Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.
Korbonits M; Kipnes M; Grossman AB
Int J Clin Pract; 2004 Nov; 58(11):1073-80. PubMed ID: 15605676
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
13. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
Dobs A; Norwood P; Potts S; Gould E; Chitra S
J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
[TBL] [Abstract][Full Text] [Related]
14. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
15. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
16. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
Meikle AW; Matthias D; Hoffman AR
BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
[TBL] [Abstract][Full Text] [Related]
17. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.
Kim ED; McCullough A; Kaminetsky J
BJU Int; 2016 Apr; 117(4):677-85. PubMed ID: 26496621
[TBL] [Abstract][Full Text] [Related]
18. A novel testosterone 2% gel for the treatment of hypogonadal males.
Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y
J Androl; 2012; 33(4):601-7. PubMed ID: 21979302
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
[TBL] [Abstract][Full Text] [Related]
20. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
